{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:15:35Z","timestamp":1778624135528,"version":"3.51.4"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Eisai Europe Ltd."},{"name":"Eisai Europe Ltd."}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.yebeh.2018.01.039","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T04:44:37Z","timestamp":1522125877000},"page":"91-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Antiepileptic drug treatment of generalized tonic\u2013clonic seizures: An evaluation of regulatory data and five criteria for drug selection"],"prefix":"10.1016","volume":"82","author":[{"given":"Simon D.","family":"Shorvon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro E.","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayana A.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8120-0300","authenticated-orcid":false,"given":"Gilles","family":"Huberfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reetta","family":"K\u00e4lvi\u00e4inen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2018.01.039_bb0005","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.yebeh.2015.12.018","article-title":"Understanding the burden of idiopathic generalized epilepsy in the United States, Europe, and Brazil: an analysis from the National Health and Wellness Survey","volume":"55","author":"Gupta","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0010","first-page":"A402","article-title":"The burden of primary generalized tonic\u2013clonic seizures in Europe and the United States: an analysis of the National Health and Wellness Survey","volume":"17","author":"Gupta","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0015","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.yebeh.2013.05.020","article-title":"Neuropsychological and psychiatric outcomes in poorly controlled idiopathic generalized epilepsy","volume":"28","author":"Sarkis","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0020","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1528-1167.2011.03213.x","article-title":"Predictors of health-related quality of life and costs in adults with epilepsy: a systematic review","volume":"52","author":"Taylor","year":"2011","journal-title":"Epilepsia"},{"issue":"Suppl. 7","key":"10.1016\/j.yebeh.2018.01.039_bb0025","first-page":"1","article-title":"ILAE epidemiology commission report: introduction to the supplement","volume":"52","author":"Hesdorffer","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1528-1167.2011.03354.x","article-title":"Do antiepileptic drugs or generalized tonic\u2013clonic seizure frequency increase SUDEP risk? A combined analysis","volume":"53","author":"Hesdorffer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2006.10.002","article-title":"Sudden unexpected death in epilepsy patients: risk factors. A systematic review","volume":"16","author":"Mont\u00e9","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/epi.13604","article-title":"The burden of premature mortality of epilepsy in high-income countries: a systematic review from the Mortality Task Force of the International League Against Epilepsy","volume":"58","author":"Thurman","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.seizure.2011.10.009","article-title":"Physical injuries in patients with epilepsy and their associated risk factors","volume":"21","author":"Asadi-Pooya","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0050","article-title":"Injuries in epilepsy: a review of its prevalence, risk factors, type of injuries and prevention","volume":"1","author":"Nguyen","year":"2009","journal-title":"Neurol Int"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0055","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1017\/S0012162205000228","article-title":"Cognitive function in idiopathic generalized epilepsy of childhood","volume":"47","author":"Henkin","year":"2005","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0060","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.50.5.1377","article-title":"Recurrent seizures may cause hippocampal damage in temporal lobe epilepsy","volume":"50","author":"K\u00e4lvi\u00e4inen","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0065","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.neuroimage.2009.01.055","article-title":"Thalamo-cortical network pathology in idiopathic generalized epilepsy: insights from MRI-based morphometric correlation analysis","volume":"46","author":"Bernhardt","year":"2009","journal-title":"Neuroimage"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0070","author":"Essential Evidence Plus"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0075","series-title":"Tegretol tablets 100mg, 200mg, 400mg","author":"Carbamazepine SPC","year":"2015"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0080","series-title":"Tegretol prolonged release 200mg and 400mg tablets","author":"Carbamazepine Prolonged Release SPC","year":"2016"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0085","series-title":"Frisium 10mg tablets","author":"Clobazam SPC","year":"2017"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0090","series-title":"Lamictal","author":"Lamotrigine SPC","year":"2017"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0095","series-title":"Keppra 1000mg film-coated tablets","author":"Levetiracetam SPC","year":"2010"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0100","series-title":"Fycompa 2mg, 4mg, 6mg, 8mg, 10mg, 12mg film-coated tablets","author":"Perampanel SPC","year":"2017"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0105","series-title":"Epaneutin 30mg\/5ml oral suspension","author":"Phenytoin SPC","year":"2017"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0110","series-title":"Topamax 100mg tablets","author":"Topiramate SPC","year":"2017"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0115","series-title":"Epilim 100mg crushable tablets","author":"Valproate SPC","year":"2017"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0120","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0125","author":"EMA"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0130","author":"Sabat\u00e9"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0135","first-page":"e22","article-title":"Effect of medication dosing frequency on adherence in chronic diseases","volume":"15","author":"Saini","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0140","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40271-013-0020-5","article-title":"Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism","volume":"6","author":"Lalibert\u00e9","year":"2013","journal-title":"Patient"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0145","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.yebeh.2003.08.013","article-title":"Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy","volume":"4","author":"Doughty","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0150","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1001\/jama.1989.03420220087032","article-title":"How often is medication taken as prescribed? A novel assessment technique","volume":"261","author":"Cramer","year":"1989","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0155","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.4","article-title":"Quantification of the forgiveness of drugs to imperfect adherence","volume":"4","author":"Assawasuwannakit","year":"2015","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0165","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022780","article-title":"Mechanisms of action of antiseizure drugs and the ketogenic diet","volume":"6","author":"Rogawski","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0170","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1212\/01.wnl.0000187118.19221.e4","article-title":"Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic\u2013clonic seizures","volume":"65","author":"Biton","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0175","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.yebeh.2010.07.022","article-title":"Adjunctive lamotrigine XR for primary generalized tonic\u2013clonic seizures in a randomized, placebo-controlled study","volume":"19","author":"Biton","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0180","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0185","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic\u2013clonic seizures in idiopathic generalized epilepsy a randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0190","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.52.7.1330","article-title":"A randomized, placebo-controlled study of topiramate in primary generalized tonic\u2013clonic seizures. Topiramate YTC Study Group","volume":"52","author":"Biton","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0195","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1528-1157.1998.tb01444.x","volume":"39","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0200","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/jnnp.58.1.44","article-title":"Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial","volume":"58","author":"Heller","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0205","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1212\/WNL.43.11.2284","article-title":"Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group","volume":"43","author":"Matsuo","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0210","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1528-1157.1994.tb02920.x","article-title":"Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial","volume":"35","author":"Messenheimer","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0215","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.56.5.448","article-title":"Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures","volume":"56","author":"Schapel","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0220","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1212\/01.wnl.0000277698.33743.8b","article-title":"Lamotrigine extended-release as adjunctive therapy for partial seizures","volume":"69","author":"Naritoku","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0225","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0230","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0235","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0240","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1528-1167.2008.01817.x","article-title":"Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial","volume":"50","author":"Peltola","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0245","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0250","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0255","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0260","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(96)00029-0","article-title":"Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy","volume":"25","author":"Sharief","year":"1996","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0265","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1528-1157.1999.tb01596.x","volume":"40","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0270","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1996.tb00606.x","article-title":"Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures","volume":"37","author":"Ben-Menachem","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0275","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1212\/WNL.46.6.1684","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group","volume":"46","author":"Faught","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0280","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1212\/WNL.46.6.1678","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group","volume":"46","author":"Privitera","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0285","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1034\/j.1600-0404.2002.02071.x","article-title":"Low-dose topiramate in adults with treatment-resistant partial-onset seizures","volume":"106","author":"Guberman","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0290","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/ane.12103","article-title":"Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures","volume":"127","author":"Ko","year":"2013","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0295","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM198507183130303","article-title":"Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic\u2013clonic seizures","volume":"313","author":"Mattson","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0300","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM199209103271104","article-title":"A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic\u2013clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group","volume":"327","author":"Mattson","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0305","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/j.0013-9580.2003.00403.x","article-title":"Levetiracetam and partial seizure subtypes: pooled data from three randomized, placebo-controlled trials","volume":"44","author":"Leppik","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0310","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2018.01.039_bb0315","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1111\/j.1528-1157.1997.tb04515.x","article-title":"Topiramate as adjunctive therapy in refractory partial epilepsy: pooled analysis of data from five double-blind, placebo-controlled trials","volume":"38","author":"Reife","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0320","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1528-1157.1996.tb00649.x","article-title":"Double-blind, placebo-controlled trial of topiramate (600mg daily) for the treatment of refractory partial epilepsy","volume":"37","author":"Tassinari","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0325","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009258.pub2","article-title":"Clobazam monotherapy for partial-onset or generalized-onset seizures","author":"Arya","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0330","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004154.pub4","article-title":"Clobazam as an add-on in the management of refractory epilepsy","author":"Michael","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0335","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1212\/WNL.55.8.1106","article-title":"Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy?","volume":"55","author":"Genton","year":"2000","journal-title":"Neurology"},{"issue":"Suppl. 8","key":"10.1016\/j.yebeh.2018.01.039_bb0340","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1528-1167.2009.02233.x","article-title":"Some treatments cause seizure aggravation in idiopathic epilepsies (especially absence epilepsy)","volume":"50","author":"Somerville","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0345","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrd4126","article-title":"New avenues for anti-epileptic drug discovery and development","volume":"12","author":"L\u00f6scher","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0350","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1111\/epi.12765","article-title":"Prevention of generalized tonic\u2013clonic seizures in refractory focal epilepsy: a meta-analysis","volume":"55","author":"Hemery","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0355","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0360","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2165\/00023210-199605050-00005","article-title":"Cognitive adverse effects of antiepileptic drugs: incidence, mechanisms and therapeutic implications","volume":"5","author":"K\u00e4lvi\u00e4inen","year":"1996","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0365","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.yebeh.2013.07.013","article-title":"Which drug-induced side effects would be tolerated in the prospect of seizure control?","volume":"29","author":"Witt","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0370","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.yebeh.2008.12.007","article-title":"Subjective perception of cognition is related to mood and not performance","volume":"14","author":"Marino","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0375","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1093\/brain\/aww196","article-title":"Psychotic disorders induced by antiepileptic drugs in people with epilepsy","volume":"139","author":"Chen","year":"2016","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0380","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/pr.115.012021","article-title":"Epilepsy, antiepileptic drugs, and aggression: an evidence-based review","volume":"68","author":"Brodie","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0385","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1212\/01.wnl.0000334295.50403.4c","article-title":"Cross-sensitivity of skin rashes with antiepileptic drug use","volume":"71","author":"Hirsch","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0390","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/epi.13437","article-title":"Withdrawal of valproic acid treatment during pregnancy and seizure outcome: observations from EURAP","volume":"57","author":"Tomson","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0395","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1212\/01.WNL.0000063308.22506.19","article-title":"Differential cognitive and behavioral effects of topiramate and valproate","volume":"60","author":"Meador","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0400","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/epi.13036","article-title":"Commentary: valproate in the treatment of epilepsy in women and girls: the need for recommendations","volume":"56","author":"Tomson","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0405","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1212\/WNL.0000000000001772","article-title":"Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study","volume":"85","author":"Tomson","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0410","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.yebeh.2006.03.006","article-title":"Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: a 1-year follow-up","volume":"8","author":"Lee","year":"2006","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0415","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ane.12529","article-title":"Perampanel for focal epilepsy: insights from early clinical experience","volume":"133","author":"Trinka","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0420","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/j.1528-1167.2008.01799.x","article-title":"The role of titration schedule of topiramate for the development of depression in patients with epilepsy","volume":"50","author":"Mula","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0425","article-title":"Chapter 4: principles of therapy in epilepsies","author":"Panayiotopoulos","year":"2005"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2016.02.001","article-title":"Treatment non-adherence in pseudo-refractory epilepsy","volume":"122","author":"Brodtkorb","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0440","first-page":"33","article-title":"Adherence to medication among outpatient adolescents with epilepsy","volume":"23","author":"Gabr","year":"2015","journal-title":"Saudi Pharm J SPJ Off Publ Saudi Pharm Soc"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0445","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.yebeh.2015.06.040","article-title":"Behavioral predictors of medication adherence trajectories among youth with newly diagnosed epilepsy","volume":"50","author":"Loiselle","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0450","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/nedt.2007.3.1.117","article-title":"Managing patient adherence and quality of life in epilepsy","volume":"3","author":"Eatock","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0455","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jama.2011.506","article-title":"Patterns of nonadherence to antiepileptic drug therapy in children with newly diagnosed epilepsy","volume":"305","author":"Modi","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0460","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/jpepsy\/jsu010","article-title":"An examination of 1-year adherence and persistence rates to antiepileptic medication in children with newly diagnosed epilepsy","volume":"40","author":"Aylward","year":"2015","journal-title":"J Pediatr Psychol"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0465","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1525-5050(02)00037-9","article-title":"The relationship between poor medication compliance and seizures","volume":"3","author":"Cramer","year":"2002","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0470","doi-asserted-by":"crossref","first-page":"a022863","DOI":"10.1101\/cshperspect.a022863","article-title":"Glutamatergic mechanisms associated with seizures and epilepsy","volume":"5","author":"Barker-Haliski","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0475","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pneurobio.2003.11.003","article-title":"Emergent properties of CNS neuronal networks as targets for pharmacology: application to anticonvulsant drug action","volume":"72","author":"Faingold","year":"2004","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0480","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.brainres.2004.03.081","article-title":"Convulsive seizures induced by alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid microinjection into the mesencephalic reticular formation in rats","volume":"1021","author":"Ishimoto","year":"2004","journal-title":"Brain Res"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0485","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1006\/exnr.2000.7401","article-title":"Characterization of audiogenic-like seizures in naive rats evoked by activation of AMPA and NMDA receptors in the inferior colliculus","volume":"164","author":"Yasuda","year":"2000","journal-title":"Exp Neurol"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0490","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2174\/1871527311312030015","article-title":"Does mechanism of drug action matter to inform rational polytherapy in epilepsy?","volume":"12","author":"Giussani","year":"2013","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0495","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl. 8","key":"10.1016\/j.yebeh.2018.01.039_bb0500","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1167.2009.02238.x","article-title":"Rational polytherapy","volume":"50","author":"French","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.01.039_bb0505","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"Margolis","year":"2014","journal-title":"JAMA Neurol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017310727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017310727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T16:00:13Z","timestamp":1668787213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505017310727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":100,"alternative-id":["S1525505017310727"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.01.039","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiepileptic drug treatment of generalized tonic\u2013clonic seizures: An evaluation of regulatory data and five criteria for drug selection","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.01.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}